339 related articles for article (PubMed ID: 20833333)
1. SDH-related pheochromocytoma and paraganglioma.
Kantorovich V; King KS; Pacak K
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):415-24. PubMed ID: 20833333
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
3. MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.
Dona M; Neijman K; Timmers HJLM
Int J Biochem Cell Biol; 2021 May; 134():105949. PubMed ID: 33609747
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional consequences of succinate dehydrogenase subunit B mutations.
Kim E; Rath EM; Tsang VH; Duff AP; Robinson BG; Church WB; Benn DE; Dwight T; Clifton-Bligh RJ
Endocr Relat Cancer; 2015 Jun; 22(3):387-97. PubMed ID: 25972245
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect.
Moosavi B; Zhu XL; Yang WC; Yang GF
Eur J Cell Biol; 2020 Jan; 99(1):151057. PubMed ID: 31810635
[TBL] [Abstract][Full Text] [Related]
6. [Succinate dehydrogenase in cancer].
Moog S; Favier J
Med Sci (Paris); 2022 Mar; 38(3):255-262. PubMed ID: 35333162
[TBL] [Abstract][Full Text] [Related]
7. Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes.
Withey SJ; Perrio S; Christodoulou D; Izatt L; Carroll P; Velusamy A; Obholzer R; Lewington V; Jacques AET
Radiographics; 2019; 39(5):1393-1410. PubMed ID: 31498738
[TBL] [Abstract][Full Text] [Related]
8. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
9. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications.
Barletta JA; Hornick JL
Adv Anat Pathol; 2012 Jul; 19(4):193-203. PubMed ID: 22692282
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma.
Hensen EF; Bayley JP
Fam Cancer; 2011 Jun; 10(2):355-63. PubMed ID: 21082267
[TBL] [Abstract][Full Text] [Related]
12. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
13. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations.
Bayley JP; Oldenburg RA; Nuk J; Hoekstra AS; van der Meer CA; Korpershoek E; McGillivray B; Corssmit EP; Dinjens WN; de Krijger RR; Devilee P; Jansen JC; Hes FJ
BMC Med Genet; 2014 Oct; 15():111. PubMed ID: 25300370
[TBL] [Abstract][Full Text] [Related]
14. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
Gupta S; Zhang J; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
16. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
17. Models of parent-of-origin tumorigenesis in hereditary paraganglioma.
Hoekstra AS; Devilee P; Bayley JP
Semin Cell Dev Biol; 2015 Jul; 43():117-124. PubMed ID: 26067997
[TBL] [Abstract][Full Text] [Related]
18. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
Nakamura E; Kaelin WG
Endocr Pathol; 2006; 17(2):97-106. PubMed ID: 17159241
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
